HomeCompareACGN vs EPRT

ACGN vs EPRT: Dividend Comparison 2026

ACGN yields 519.62% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ACGN wins by $82785.58M in total portfolio value
10 years
ACGN
ACGN
● Live price
519.62%
Share price
$0.38
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$82785.64M
Annual income
$60,051,464,507.48
Full ACGN calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — ACGN vs EPRT

📍 ACGN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodACGNEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ACGN + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ACGN pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ACGN
Annual income on $10K today (after 15% tax)
$44,167.32/yr
After 10yr DRIP, annual income (after tax)
$51,043,744,831.36/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, ACGN beats the other by $51,043,733,916.74/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ACGN + EPRT for your $10,000?

ACGN: 50%EPRT: 50%
100% EPRT50/50100% ACGN
Portfolio after 10yr
$41392.85M
Annual income
$30,025,738,674.10/yr
Blended yield
72.54%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

ACGN
No analyst data
Altman Z
-10.8
Piotroski
3/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ACGN buys
0
EPRT buys
0
No recent congressional trades found for ACGN or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricACGNEPRT
Forward yield519.62%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$82785.64M$63.4K
Annual income after 10y$60,051,464,507.48$12,840.73
Total dividends collected$80827.26M$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: ACGN vs EPRT ($10,000, DRIP)

YearACGN PortfolioACGN Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$62,662$51,961.55$11,205$505.18+$51.5KACGN
2$371,346$304,298.23$12,672$682.46+$358.7KACGN
3$2,082,703$1,685,362.72$14,490$930.48+$2.07MACGN
4$11,062,507$8,834,014.38$16,786$1,282.69+$11.05MACGN
5$55,690,004$43,853,122.08$19,753$1,791.56+$55.67MACGN
6$265,907,885$206,319,580.72$23,677$2,541.64+$265.88MACGN
7$1,205,205,519$920,684,081.82$29,008$3,672.99+$1205.18MACGN
8$5,189,499,372$3,899,929,466.64$36,463$5,425.08+$5189.46MACGN
9$21,246,897,259$15,694,132,931.16$47,238$8,221.57+$21246.85MACGN
10$82,785,644,575$60,051,464,507.48$63,385$12,840.73+$82785.58MACGN

ACGN vs EPRT: Complete Analysis 2026

ACGNStock

Aceragen, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare pulmonary and rheumatic diseases in the United States. Its clinical development pipeline includes ACG-701, which is in Phase 2 clinical trial for cystic fibrosis pulmonary exacerbations, as well as for melioidosis; and ACG-801 for farber disease. Aceragen, Inc. has a collaboration and option agreement with Scriptr Global, Inc. to identify, research, and develop gene therapy candidates for the treatment, palliation, diagnosis, or prevention of myotonic dystrophy type 1 and Friedreich's Ataxia. The company was formerly known as Idera Pharmaceuticals, Inc. and changed its name to Aceragen, Inc. in January 2023. Aceragen, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.

Full ACGN Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this ACGN vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ACGN vs SCHDACGN vs JEPIACGN vs OACGN vs KOACGN vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.